Skip to main
EWTX

Edgewise Therapeutics (EWTX) Stock Forecast & Price Target

Edgewise Therapeutics (EWTX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Edgewise Therapeutics is making a strategic move by divesting its sevasemten franchise to focus on its cardiovascular franchise, which includes potential blockbuster drugs EDG-7500 and EDG-15400. This transaction will provide the company with non-dilutive financing and allow it to concentrate its resources on its promising cardiac treatments. Additionally, the ongoing CIRRUS trials for EDG-7500 show favorable results and have the potential to demonstrate a differentiated profile among other cardiovascular medications. With multiple upcoming catalysts and a novel approach to treating serious cardiac conditions, Edgewise Therapeutics has significant potential for growth.

Bears say

Edgewise Therapeutics is facing significant risks due to uncertainty surrounding their product candidates and potential competition in the market for muscular dystrophy and cardiac treatments. The company's financial future also relies heavily on their current product pipeline, making them vulnerable to any setbacks or failures in clinical trials. Despite a recent cash infusion from a partnership deal, the company's financial stability may still be at risk as they continue to invest in research and development and prepare for potential commercialization. Additionally, there is potential for limited synergies in the business as their product offerings require different expertise and target different markets, potentially limiting their overall success. Overall, the outlook for Edgewise Therapeutics is uncertain and carries a high level of risk.

Edgewise Therapeutics (EWTX) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edgewise Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edgewise Therapeutics (EWTX) Forecast

Analysts have given Edgewise Therapeutics (EWTX) a Buy based on their latest research and market trends.

According to 6 analysts, Edgewise Therapeutics (EWTX) has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edgewise Therapeutics (EWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.